Moderna and Merck's mRNA Cancer Vaccine Achieves Success in Phase 3 Melanoma Trial
Product·3 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Moderna and Merck's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win sets the partners up to potentially seek accelerated approval.
The trial results indicate that the vaccine succeeded in slowing recurrence rates, marking a significant advancement in cancer treatment. This achievement positions Moderna and Merck to push for regulatory approval in the near future.
ModernaMerck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say”
Ars Technica — mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say“Merck & Co.”
fierce biotech — <a href="/biotech/merck-and-modernas-personalized-cancer-vaccine-slows-recurrence-ph-3-trial" hreflang="en">Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push</a>